Clinical significance of Beta-2 glycoprotein I antibodies in BcrAbl (-) myeloproliferative neoplasms

Basit Öğe Kaydı
dc.contributor.authorKocak, Mehmet Zahid
dc.contributor.authorDagli, Mehmet
dc.contributor.authorUnlu, Ali
dc.date.accessioned2020-03-26T19:34:22Z
dc.date.available2020-03-26T19:34:22Z
dc.date.issued2017
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Beta-2 glycoprotein I antibodies (B2-GPI Ab) are significant markers of thrombosis in otoimmune diseases. No literature has been found in Bcr Abl (-) MPNs to exclude the risk of hereditary thrombophilia and to investigate the association of B2-GPI Ab levels with thrombosis. This study aimed to investigate the relation between levels of B2-GPI Ab and thrombosis in BcrAbl (-) MPN without the risk of hereditary thrombophilia. Methods: Plasma samples from healthy volunteers and BcrAbl (-) MPN's patients with and without thrombosis were collected after receiving consent. B2-GPI Ab in plasma was quantified by enzyme-linked immunosorbent assay and the data were analyzed to determine whether plasma.2-GPI Ab correlates significantly with thrombosis. Result: There was a statistically significant difference between the B2-GPI Ab levels of the patients and the control group (p=0.006). However, no statistically significant difference in levels of B2-GPI between patients with and without thrombosis history was determined (p=0.144). Conclusion: This study supports that no relationship between levels of B2-GPI Ab and thrombosis complications in BcrAbl (-) MPN.en_US
dc.description.sponsorshipSelcuk University, Scientific Research ProjectsSelcuk University [15102015]en_US
dc.description.sponsorshipThis study was supported by Selcuk University, Scientific Research Projects (Project Number: 15102015).en_US
dc.identifier.endpage2829en_US
dc.identifier.issn0970-938Xen_US
dc.identifier.issn0976-1683en_US
dc.identifier.issue6en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage2826en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/34885
dc.identifier.volume28en_US
dc.identifier.wosWOS:000403448200079en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherALLIED ACADen_US
dc.relation.ispartofBIOMEDICAL RESEARCH-INDIAen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectMyeloproliferative neoplasmsen_US
dc.subjectPolicythaemia veraen_US
dc.subjectEssential thrombocytosisen_US
dc.subjectBeta-2 glycoprotein I antibodyen_US
dc.subjectThrombosisen_US
dc.titleClinical significance of Beta-2 glycoprotein I antibodies in BcrAbl (-) myeloproliferative neoplasmsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu